Dr Reddy's sued for 'infringing' thyroid injection patent

MUMBAI: The Nifty was comfortably placed near 5,950 levels after bouncing back in the positive terrain on Friday led by gains in technology, healthcare and FMCG sectors. According to analysts, the market is likely to remain rangebound around current ...

City-based Dr Reddy's Laboratories Ltd (DRL) on Monday said it terminated its contract with Fujifilm to establish a joint venture and an exclusive partnership for generic drugs business in the Japanese market. The move is triggered by Fujifilm's ...

The Sensex was down 49.19 points at 20163.77, and the Nifty fell 18.50 points to 6128.25. About 152 shares have advanced, 94 shares declined, and 34 shares are unchanged.

EBITDA margins posted at Rs 27.8 billion in FY13 Dr Reddy's Laboratories (DRL) announced its audited consolidated financial results for the fourth quarter and full year ended March 31, 2013 under International Financial Reporting Standards (IFRS).

Realty, banking, capital goods, oil and gas were supporting the index.

Aided by robust sales from North America and emerging markets, pharma major Dr Reddy's Laboratories Ltd (DRL) on Tuesday reported a 66.6 per cent increase in its net profit at Rs 571.01 crore for the quarter ended March, 2013 as against Rs 342.70 ...

One can buy Dr Reddys Laboratories, says Sudarshan Sukhani of s2analytics.com. "When the Nifty corrected 250 points, DRL consolidated. This consolidation probably could easily breakout today," he adds.

The trade is likely to turn choppy as the session progresses ahead of May F series expiry, say dealers. "The US markets pulled back off after moving sharply higher in early trading but managed to end the day in positive territory," said an Angel Broking note.

In yet another patent infringement suit, Dr Reddy's Laboratories Ltd (DRL), has been dragged to court by US-based Fresenius Kabi for allegedly infringing the latter's patents. According to Kabi, DRL has violated patents of its injected anaesthetic ...